AnaptysBio, Inc. (ANAB) News
Filter ANAB News Items
ANAB News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ANAB News Highlights
- For ANAB, its 30 day story count is now at 2.
- Over the past 2 days, the trend for ANAB's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- GPP and RARE are the most mentioned tickers in articles about ANAB.
Latest ANAB News From Around the Web
Below are the latest news stories about Anaptysbio Inc that investors may wish to consider to help them evaluate ANAB as an investment opportunity.
AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of PsoriasisAnaptysBio Inc (NASDAQ: ANAB) has announced updated data from the GALLOP Phase 2 trial of imsidolimab in generalized pustular psoriasis (GPP). GPP is a rare and extreme form of psoriasis characterized by the presence of sterile pustules. The 16-week data were presented at the 2021 European Academy of Dermatology and Venereology (EADV) Congress. Data from 8 patients showed that 6/8 patients treated with imsidolimab monotherapy achieved the primary endpoint of response on the clinical global impre |
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular PsoriasisImsidolimab demonstrated rapid and sustained efficacy with 6 of 8 (75%) generalized pustular psoriasis (GPP) patients achieving the primary endpoint at week 4 and week 16Early reduction of erythema with pustules by 60% at week 1 improved to 94% reduction at week 4 and 98% reduction at week 16Phase 3 GEMINI-1 clinical trial has been initiated subsequent to FDA end-of-Phase 2 meeting and FDA orphan drug designation for the treatment of GPPIn addition to GPP, imsidolimab clinical development to foc |
Anaptysbio Inc (ANAB): Price Now Near $26.51; Daily Chart Shows An Uptrend on 20 Day BasisThe moving averages on the daily timeframe suggest a bullishness in price, as the 20, 50, 100 and 200 are all in a bullish alignment -- meaning the shorter durations are above the longer duration averages, implying a sound upward trend. The post Anaptysbio Inc (ANAB): Price Now Near $26.51; Daily Chart Shows An Uptrend on 20 Day Basis appeared first on ETF Daily News . |
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment ConferenceSAN DIEGO, Sept. 09, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that Hamza Suria, chief executive officer of AnaptysBio, will present an overview of AnaptysBio at the H.C. Wainwright 23rd Annual Global Investment Conference. The presentation will be available on Monday |
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKlineHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV) Alkermes plc (NASDAQ: ALKS) Century Therapeutics Inc (NASDAQ: IPSC) Gilead Sciences, Inc. (NASDAQ: GILD) GlaxoSmithKline plc (NYSE: GSK) Edward Lifesciences Corp (NYSE: EW) Eli Lilly and Company (NYSE: LLY) (announced reorganization of business units) Innoviva Inc (NASDAQ: INVA) Intuitive Surgical, Inc. (NASDAQ: ISRG) Johnson |
AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor IndicationThe FDA has approved a second indication for GlaxoSmithKline plc's (NYSE: GSK) Jemperli (dostarlimab-gxly). The approval comes for adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors that have progressed on or following prior treatment and have no satisfactory alternative treatment options. Jemperli was approved for dMMR endometrial cancer in the U.S. and Europe in April. Related content: Benzinga's Full FDA Calendar. Jemperli was generated by AnaptysBio Inc ( |
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid TumorsSAN DIEGO, Aug. 17, 2021 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that the U.S. Food and Drug Administration (FDA) approved a second indication for GSKs JEMPERLI (dostarlimab-gxly) for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. |
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid TumorsSecond FDA Approval of PD-1 Antagonist Antibody Under Clinical Development for Solid Tumors in Collaboration with GSKJEMPERLI Was Approved For dMMR Endometrial Cancer in the US and Europe in April 2021$20MM Milestone Payment Earned by AnaptysBio Upon Second JEMPERLI FDA Approval in Addition to $40MM Already Earned Upon Prior Regulatory Milestones During 2021Additional $15MM and $165MM Milestones Due Upon Achievement of JEMPERLI Regulatory and Commercial Milestones, RespectivelyAnaptysBio Due to |
Global Netherton Syndrome Market 2021-2030 Featuring Major Players - Lifemax Laboratories and AnaptysBioDublin, Aug. 12, 2021 (GLOBE NEWSWIRE) -- The "Netherton Syndrome Market Insight, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com''s offering. This ''Netherton Syndrome - Market Insights, Epidemiology, and Market Forecast - 2030'' report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of Netherton Syndrome in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. Netherton Syndrome Epidemiology The Netherton Syndrome epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studi... |
Peanut Allergy Pipeline Insight Report Proffers Clinical Trials Updates, Including Detailed Profiles of Emerging Drugs Along With CompaniesLos Angeles, USA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Peanut Allergy Pipeline Insight Report Proffers Clinical Trials Updates, Including Detailed Profiles of Emerging Drugs Along With Companies Approximately 10+ key companies are developing therapies for Peanut Allergy treatment. DBV Technologies has its drug candidates in the most advanced stage. The use of new biological compounds is considered to have the potential to treat the disease, which is expected to improve the treatment method in Peanut Allergy patients. DelveInsight''s " Peanut Allergy Pipeline Insight " report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Peanut Allergy pipeline landscapes. It comprises Peanut Allergy pipeline drug profiles, including clinical and non-clinical stage produc... |